Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sarepta Therapeutics 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 USA

www.sarepta.com P: 617-274-4000 F: 800-621-5203

Description:

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.

Key Statistics

Overview:

Market Capitalization, $K 12,735,488
Enterprise Value, $K 13,312,998
Shares Outstanding, K 93,547
Annual Sales, $ 933,010 K
Annual Net Income, $ -703,490 K
Last Quarter Sales, $ 331,820 K
Last Quarter Net Income, $ -40,940 K
EBIT, $ -398,300 K
EBITDA, $ -356,440 K
60-Month Beta 0.93
% of Insider Shareholders 7.40%
% of Institutional Shareholders 91.82%
Float, K 86,625
% Float 92.60%
Short Volume Ratio 0.51

Growth:

1-Year Return 8.51%
3-Year Return 51.95%
5-Year Return -9.82%
5-Year Revenue Growth 503.58%
5-Year Earnings Growth -389.63%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.46 on 11/01/23
Latest Earnings Date 02/27/24
Earnings Per Share ttm -3.41
EPS Growth vs. Prev Qtr -70.37%
EPS Growth vs. Prev Year 84.35%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 07/12/12

SRPT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 55.31
Price/Earnings to Growth N/A
Return-on-Equity % -46.23%
Return-on-Assets % -9.69%
Profit Margin % -75.40%
Debt/Equity 1.62
Price/Sales 10.59
Price/Cash Flow N/A
Price/Book 15.50
Book Value/Share 8.69
Interest Coverage -0.53
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar